SEED Therapeutics Receives IND Clearance from China’s NMPA for ST-01156
China Sites to Join Upcoming Global Expansion Study Evaluating RBM39-Dependent Cancers King of Prussia, PA – November 12, 2025 – SEED Therapeutics, Inc. (“SEED”),…
Press Releases
SEED Therapeutics Completes $30 Million Series A-3 Financing
King of Prussia, PA – September 23, 2025 – SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable…
20 Years of the Ubiquitin Revolution: Honoring Nobel Laureate Professor Avram Hershko and the Future of Targeted Protein Degradation
New York, NY – September 9, 2025 – Leaders in the fields of ubiquitin biology and targeted protein degradation (TPD) gathered on September 6, 2025,…
SEED Therapeutics Named Finalist for 2025 Prix Galien USA “Best Start-Up” Award
Nomination recognizes SEED’s pioneering work in molecular glue development in targeted protein degradation to address high unmet medical needs Follows recent FDA IND clearance…
FDA Clears IND for SEED Therapeutics’ RBM39 Degrader ST-01156
First Patient Dosing Expected in Q1 2026 Clinical Trial to Prioritize Biomarker-Selected RBM39-Dependent Cancers King of Prussia, PA – August 11, 2025 –…
SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer
King of Prussia, PA – June 9, 2025 – SEED Therapeutics Inc. (“SEED”), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery of…
SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025
Novel RBM39 molecular glue achieves complete tumor regression in mechanism-based Ewing sarcoma models; IND filing expected mid-2025 Dual PROTAC strategy overcomes hook effect and…
SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago
Two PROTAC synergy using two E3 ligases for achieving levels of degradation of KRAS G12D not achieved with single PROTACs, will be presented by…
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
King of Prussia, PA – January 28, 2025 – SEED Therapeutics Inc. (“SEED”), a biotechnology company pioneering the discovery of molecular glues for targeted protein…
Nature: Protein degraders push into novel target space
Clinic-ready molecular glues and heterobifunctional PROTAC drugs are taking targeted protein degradation into uncharted territory. Learn More
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
Mizui is Founder and President of Eisai Innovations, Inc. and Former Global Business Development and Strategy Head in Eisai’s Oncology Business Group Brings Nearly…
SEED Concurrently Enters into Share Purchase Agreements for its Series A-3 Financing Led by Eisai
The SEED-Eisai Research Collaboration leverages Eisai’s leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of up to…
SEED Therapeutics is Featured Prominently in a Molecular Glue Development Publication, Nature Biotechnology
March 6, 2024: Nature Biotechnology, a transformative journal covering the science and business of biotechnology, published a review article on the significant challenges facing…
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
NEW YORK, October 26, 2023 – SEED Therapeutics Inc. (“SEED”), a biotech company focused on harnessing and engineering Molecular Glues for targeted protein degradation…
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors Former Eisai Board Member, Former World Bank General Counsel, and Lecturer at Harvard and Yale Law Schools, Brings Five Decades of Experience in Global Health, Law, Governance, and International Business
NEW YORK, October 23, 2023 – SEED Therapeutics (SEED), an innovative global biotech company focused on engineering “molecular glues” and harnessing its targeted protein degradation (TPD) platform…
Seed Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
New York, NY – June 20, 2023 – SEED Therapeutics (the “Company”), a BeyondSpring (NASDAQ: BYSI) subsidiary and global research company focused on harnessing and engineering “molecular glues,”…
Seed Therapeutics has completed construction of a new state of the art innovation and research center at 411 Swedeland Road in King of Prussia, Pennsylvania.
King of Prussia, PA – July 01, 2022 – Seed Therapeutics has completed construction of a state of the art 10,000 square foot innovation and…
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly
Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines. NEW YORK – November 13, 2020 – Seed Therapeutics (“the…
BeyondSpring Creates Subsidiary, Seed Therapeutics, to Focus on Protein Degradation Platform
“Molecular Glue” Protein Degradation Serves as Alternative Approach to Cancer Treatment NEW YORK – August 7, 2020 – Seed Therapeutics Inc. (the “Company” or…